{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:17:16Z","timestamp":1791346636190,"version":"4.3.1"},"reference-count":251,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ24H300004"],"award-info":[{"award-number":["LQ24H300004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC3403200"],"award-info":[{"award-number":["2023YFC3403200"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32301165"],"award-info":[{"award-number":["32301165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.apsb.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:55:06Z","timestamp":1771833306000},"page":"2903-2928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-viral delivery of genome-editing tools for treatment of genetic disorders"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7890-7083","authenticated-orcid":false,"given":"Jiamin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-7721","authenticated-orcid":false,"given":"Yuan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.02.014_bib1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41576-023-00621-w","article-title":"Genomic newborn screening for rare diseases","volume":"24","author":"Stark","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41591-024-03465-x","article-title":"Population-based, first-tier genomic newborn screening in the maternity ward","volume":"31","author":"Boemer","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib7","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib11","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In vivo somatic cell base editing and prime editing","volume":"29","author":"Newby","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine Hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib14","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41578-019-0145-9","article-title":"Engineered materials for in vivo delivery of genome-editing machinery","volume":"4","author":"Tong","year":"2019","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.apsb.2026.02.014_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/43977","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrc1122","article-title":"Occurrence of leukaemia following gene therapy of X-linked SCID","volume":"3","author":"Kohn","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.02.014_bib20","article-title":"Engineered nanomaterials to potentiate CRISPR\/Cas9 gene editing for cancer therapy","volume":"36","author":"Yi","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.02.014_bib21","article-title":"Carrier strategies boost the application of CRISPR\/Cas system in gene therapy","volume":"2","author":"Xu","year":"2022","journal-title":"Explorations"},{"key":"10.1016\/j.apsb.2026.02.014_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-viral delivery to enable genome editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.02.014_bib24","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/j.1460-2075.1985.tb03825.x","article-title":"Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes","volume":"4","author":"Miller","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2026.02.014_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/jmbi.2001.4635","article-title":"FokI requires two specific DNA sites for cleavage","volume":"309","author":"Vanamee","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.1178817","article-title":"A simple cipher governs DNA recognition by TAL effectors","volume":"326","author":"Moscou","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.02.014_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature17945","article-title":"The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA","volume":"532","author":"Fonfara","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib38","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aar6245","article-title":"CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity","volume":"360","author":"Chen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2217T to G\u2217C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib42","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","author":"Komor","year":"2017","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.02.014_bib45","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41587-019-0236-6","article-title":"CRISPR DNA base editors with reduced RNA off-target and self-editing activities","volume":"37","author":"Grunewald","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aba8853","article-title":"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants","volume":"368","author":"Walton","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib48","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12076","article-title":"Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing","volume":"10","author":"Yao","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.apsb.2026.02.014_bib50","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0020133","article-title":"A look to future directions in gene therapy research for monogenic diseases","volume":"2","author":"Porteus","year":"2006","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib55","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-binding protein","volume":"628","author":"Yan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.34133\/bdr.0041","article-title":"CRISPR-Cas13: pioneering RNA editing for nucleic acid therapeutics","volume":"6","author":"Zhu","year":"2024","journal-title":"Biodes Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41587-022-01419-7","article-title":"High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects","volume":"41","author":"Tong","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib61","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41592-021-01124-4","article-title":"Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes","volume":"18","author":"Xu","year":"2021","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.02.014_bib62","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib63","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.aax7063","article-title":"A cytosine deaminase for programmable single-base RNA editing","volume":"365","author":"Abudayyeh","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib65","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/pbi.13383","article-title":"Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective","volume":"18","author":"Zhang","year":"2020","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.apsb.2026.02.014_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3107","article-title":"Delivery of CRISPR\/Cas9 for therapeutic genome editing","volume":"21","author":"Xu","year":"2019","journal-title":"J Gene Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib67","first-page":"6","volume":"36","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd3572-c1","article-title":"Glybera and the future of gene therapy in the European Union","volume":"11","author":"Miller","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib69","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib70","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib71","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib72","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1039\/C8BM01310A","article-title":"Biomaterials as vectors for the delivery of CRISPR-Cas9","volume":"7","author":"Eoh","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib73","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.02.014_bib74","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib75","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.gene.2019.05.008","article-title":"Improved translation efficiency of therapeutic mRNA","volume":"707","author":"Zarghampoor","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.apsb.2026.02.014_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5701","article-title":"Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice","volume":"12","author":"Willis","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/science.1247997","article-title":"Structures of Cas9 endonucleases reveal RNA-mediated conformational activation","volume":"343","author":"Jinek","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib80","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/nprot.2015.117","article-title":"Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells","volume":"10","author":"Liu","year":"2015","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2026.02.014_bib81","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2026.02.014_bib82","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib83","article-title":"Novel vectors and approaches for gene therapy in liver diseases","volume":"3","author":"Maestro","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.apsb.2026.02.014_bib84","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","article-title":"Tyrosinemia: a review","volume":"4","author":"Russo","year":"2001","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.apsb.2026.02.014_bib85","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1089\/hum.2017.252","article-title":"Curative ex vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1","volume":"29","author":"VanLith","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib86","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib87","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1073\/pnas.98.2.641","article-title":"Point mutations in the murine fumarylacetoacetate hydrolase gene: animal models for the human genetic disorder hereditary tyrosinemia type 1","volume":"98","author":"Aponte","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.02.014_bib88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103470","article-title":"Gene and cell therapy approaches for familial hypercholesterolemia: an update","volume":"28","author":"Parsamanesh","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.02.014_bib90","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/genes12010066","article-title":"The LDLR, APOB, and PCSK9 variants of index patients with familial hypercholesterolemia in Russia","volume":"12","author":"Meshkov","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.apsb.2026.02.014_bib91","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s10038-021-00924-y","article-title":"Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India","volume":"66","author":"Reddy","year":"2021","journal-title":"J Hum Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib92","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2026.02.014_bib93","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.3390\/ijms23084281","article-title":"APOB CRISPR-Cas9 engineering in hypobetalipoproteinemia: a promising tool for functional studies of novel variants","volume":"23","author":"Vanhoye","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib94","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient CRISPR\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.02.014_bib96","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.apsb.2026.02.014_bib98","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2026.02.014_bib99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib101","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jnc.15233","article-title":"Targeting transthyretin-mechanism-based treatment approaches and future perspectives in hereditary amyloidosis","volume":"156","author":"Dohrn","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2026.02.014_bib102","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse Paula","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.apsb.2026.02.014_bib104","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","article-title":"Inhibition of prekallikrein for hereditary angioedema","volume":"386","author":"Fijen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-8587(17)30201-2","article-title":"Issues with European guidelines for phenylketonuria","volume":"5","author":"Burgard","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apsb.2026.02.014_bib106","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib107","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.apsb.2026.02.014_bib108","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s11427-020-1744-6","article-title":"Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor","volume":"65","author":"Yin","year":"2022","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib109","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.ajhg.2023.10.005","article-title":"Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need","volume":"110","author":"Brooks","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.apsb.2026.02.014_bib110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz David","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib111","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.02.014_bib112","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMra022387","article-title":"Hydrophobic surfactant proteins in lung function and disease","volume":"347","author":"Whitsett","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib113","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.addr.2020.05.002","article-title":"Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders","volume":"168","author":"Wan","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1164\/ajrccm.161.3.9903153","article-title":"Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency","volume":"161","author":"Nogee","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1203\/00006450-200009000-00003","article-title":"Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation","volume":"48","author":"Dunbar","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib117","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1177\/1535370217713000","article-title":"Featured article: electroporation-mediated gene delivery of surfactant protein B (SP-B) restores expression and improves survival in mouse model of SP-B deficiency","volume":"242","author":"Barnett","year":"2017","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib118","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1038\/s41467-020-17577-8","article-title":"A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency","volume":"11","author":"Kang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib119","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt.3241","article-title":"In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency","volume":"33","author":"Mahiny","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib120","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jcf.2022.10.007","article-title":"Development of novel therapeutics for all individuals with CF (the future goes on)","volume":"22","author":"Amaral","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.apsb.2026.02.014_bib121","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.02.014_bib122","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1093\/nar\/gkab788","article-title":"Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors","volume":"49","author":"Krishnamurthy","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.01.019","article-title":"CRISPR-based adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank","volume":"26","author":"Geurts","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib124","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000940","article-title":"Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids","volume":"4","author":"Geurts","year":"2021","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.apsb.2026.02.014_bib125","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","article-title":"In vivo editing of lung stem cells for durable gene correction in mice","volume":"384","author":"Sun","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib126","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib127","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","article-title":"Membrane organization of the dystrophin\u2013glycoprotein complex","volume":"66","author":"Ervasti","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib128","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.02.014_bib129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib131","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.02.014_bib132","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","article-title":"Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing","volume":"18","author":"Hanson","year":"2021","journal-title":"RNA Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib133","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114616","article-title":"Gene editing strategies to treat lysosomal disorders: the example of mucopolysaccharidoses","volume":"191","author":"Fachel","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","article-title":"In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system","volume":"288","author":"Schuh","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib136","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.apsb.2026.02.014_bib137","first-page":"12558","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"22","author":"D\u2019Avanzo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.12.262","article-title":"Characteristics of patients with mucopolysaccharidosis type II who have received a bone marrow transplant: data from the Hunter Outcome Survey","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.apsb.2026.02.014_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.12.162","article-title":"Enzyme replacement therapy in patients with mucopolysaccharidosis type VI: updated findings from the MPS VI clinical surveillance program","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.apsb.2026.02.014_bib140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib141","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/mthe.2002.0525","article-title":"A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus","volume":"5","author":"Anand","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib142","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.addr.2020.06.011","article-title":"Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases","volume":"168","author":"Yu","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib143","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s12276-023-01057-2","article-title":"Genome editing in the treatment of ocular diseases","volume":"55","author":"Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib144","first-page":"3785","article-title":"Safety and efficacy of EDIT-101 for treatment of CEP290-associated retinal degeneration","volume":"64","author":"Pierce","year":"2023","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.addr.2020.05.001","article-title":"Advances in genome editing for genetic hearing loss","volume":"168","author":"Ding","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib146","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.2020.17647","article-title":"Hearing loss in children: a review","volume":"324","author":"Lieu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2026.02.014_bib147","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41591-019-0500-9","article-title":"Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss","volume":"25","author":"Gy\u00f6rgy","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib148","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.gene.2019.03.020","article-title":"CRISPR\/Cas9-mediated genome editing of splicing mutation causing congenital hearing loss","volume":"703","author":"Ryu","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.apsb.2026.02.014_bib149","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-016-0273-4","article-title":"Correction of the auditory phenotype in C57BL\/6N mice via CRISPR\/Cas9-mediated homology directed repair","volume":"8","author":"Miann\u00e9","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib150","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41467-018-04580-3","article-title":"In vivo base editing of post-mitotic sensory cells","volume":"9","author":"Yeh","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib151","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.ymthe.2023.10.019","article-title":"RNA base editing therapy cures hearing loss induced by OTOF gene mutation","volume":"31","author":"Xue","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib152","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.65","article-title":"Fragile X syndrome","volume":"3","author":"Hagerman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2026.02.014_bib153","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib154","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.apsb.2026.02.014_bib155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib156","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","article-title":"Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons","volume":"13","author":"Park","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.02.014_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.01.012","article-title":"Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 Gene","volume":"172","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib158","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2026.02.014_bib159","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood.V70.5.1245.1245","article-title":"Hemoglobin S gelation and sickle cell disease","volume":"70","author":"Eaton","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.02.014_bib160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1749-6632.1989.tb24159.x","article-title":"A profile of sickle cell disease in Nigeria","volume":"565","author":"Akinyanju","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib161","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147480","article-title":"CRISPR\/Cas9-based gene-editing technology for sickle cell disease","volume":"874","author":"Ma","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.apsb.2026.02.014_bib163","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib164","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib166","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature25164","article-title":"Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents","volume":"553","author":"Gao","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib167","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2026.02.014_bib168","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib169","first-page":"49","article-title":"Development of NTLA-2001, a CRISPR\/Cas9 genome editing therapeutic for the treatment of ATTR","volume":"1","author":"Wood","year":"2019","journal-title":"Life Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib170","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.02.014_bib171","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","article-title":"In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA","volume":"5","author":"Villiger","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib172","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib173","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib174","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"9","author":"Ho\u0142ubowicz","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib176","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib177","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2026.02.014_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.02.014_bib179","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib180","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s13346-012-0116-9","article-title":"Inorganic nanovectors for nucleic acid delivery","volume":"3","author":"Pranatharthiharan","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib181","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nnano.2007.223","article-title":"Immunological properties of engineered nanomaterials","volume":"2","author":"Dobrovolskaia","year":"2007","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib182","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.addr.2020.06.020","article-title":"Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles","volume":"156","author":"Luther","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib183","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/mt.2014.30","article-title":"Gold nanoparticles for nucleic acid delivery","volume":"22","author":"Ding","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib184","doi-asserted-by":"crossref","first-page":"16287","DOI":"10.1021\/ja804561g","article-title":"Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity","volume":"130","author":"Miyata","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.02.014_bib185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt.3806","article-title":"Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes","volume":"35","author":"Staahl","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib186","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2019.08.032","article-title":"Plasmonic gold nanoparticles: optical manipulation, imaging, drug delivery and therapy","volume":"311\u2013312","author":"Sharifi","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib187","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/smll.200400093","article-title":"Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity","volume":"1","author":"Connor","year":"2005","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.02.014_bib188","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbrc.2010.02.046","article-title":"Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice","volume":"393","author":"Lasagna-Reeves","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib189","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf, B"},{"key":"10.1016\/j.apsb.2026.02.014_bib190","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1021\/ar800035u","article-title":"Gold nanoparticles in biology: beyond toxicity to cellular imaging","volume":"41","author":"Murphy","year":"2008","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib191","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.taap.2008.12.023","article-title":"Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles","volume":"236","author":"Cho","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2026.02.014_bib192","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1021\/acs.molpharmaceut.8b00434","article-title":"PEGylated chitosan for nonviral aerosol and mucosal delivery of the CRISPR\/Cas9 system in vitro","volume":"15","author":"Zhang","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2026.02.014_bib193","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2009.08.004","article-title":"Chitosan-based formulations for delivery of DNA and siRNA","volume":"62","author":"Mao","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2017.07.009","article-title":"Delayed presentation and prolonged survival of a child with surfactant protein B deficiency","volume":"190","author":"Lopez-Andreu","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.apsb.2026.02.014_bib195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/(SICI)1098-1004(199912)14:6<502::AID-HUMU9>3.0.CO;2-C","article-title":"Compound SFTPB 1549C\u2014>GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency","volume":"14","author":"Tredano","year":"1999","journal-title":"Hum Mutat"},{"key":"10.1016\/j.apsb.2026.02.014_bib196","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1039\/C9CC00010K","article-title":"Cytosolic delivery of CRISPR\/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein","volume":"55","author":"Qiao","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib197","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2015.10.012","article-title":"Nanotechnology for protein delivery: overview and perspectives","volume":"240","author":"Yu","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib198","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.02.014_bib199","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202110618","article-title":"pH-responsive polymer nanoparticles for efficient delivery of Cas9 ribonucleoprotein with or without donor DNA","volume":"34","author":"Xie","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.02.014_bib200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.apsb.2026.02.014_bib201","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.11.005","article-title":"Rational designs of in vivo CRISPR-Cas delivery systems","volume":"168","author":"Xu","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib202","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122349","article-title":"A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy","volume":"302","author":"Yi","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.02.014_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102040","article-title":"Hepatocyte-confined CRISPR\/Cas9-based nanocleaver precisely eliminates viral DNA for efficient and safe treatment of hepatitis B virus infection","volume":"53","author":"Kong","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2026.02.014_bib205","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.02.014_bib206","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2026.02.014_bib207","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10048-016-0477-1","article-title":"Recessive mutations of TMC1 associated with moderate to severe hearing loss","volume":"17","author":"Imtiaz","year":"2016","journal-title":"Neurogenetics"},{"key":"10.1016\/j.apsb.2026.02.014_bib208","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154\u2013155","author":"B\u00f6ttger","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib209","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib210","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib211","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib212","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib213","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib214","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci Technol Adv Mater"},{"key":"10.1016\/j.apsb.2026.02.014_bib215","first-page":"371","article-title":"Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles","volume":"10","author":"Hwang","year":"2015","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2026.02.014_bib216","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib217","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.accounts.9b00109","article-title":"Drug delivery with extracellular vesicles: from imagination to innovation","volume":"52","author":"de Jong","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib218","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1039\/D4BM00054D","article-title":"Functionalized extracellular nanovesicles as advanced CRISPR delivery systems","volume":"12","author":"Wang","year":"2024","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib219","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.216259","article-title":"Viral escape from endosomes and host detection at a glance","volume":"131","author":"Staring","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2026.02.014_bib220","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1073\/pnas.1101874108","article-title":"Protein delivery using engineered virus-like particles","volume":"108","author":"Kaczmarczyk","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.02.014_bib221","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The endosomal escape of nanoparticles: toward more efficient cellular delivery","volume":"30","author":"Smith","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2026.02.014_bib222","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9","volume":"4","author":"Li","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apsb.2026.02.014_bib223","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","article-title":"Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy","volume":"29","author":"Cideciyan","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apsb.2026.02.014_bib224","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12642","article-title":"Reprogramming metabolic pathways in vivo with CRISPR\/Cas9 genome editing to treat hereditary tyrosinaemia","volume":"7","author":"Pankowicz","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.02.014_bib225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-023-00648-4","article-title":"An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses","volume":"8","author":"Tarr\u00e9s-Freixas","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.apsb.2026.02.014_bib226","article-title":"Virus-like particles (VLPs)-based vaccines against COVID-19: where do we stand amid the ongoing evolution of SARS-CoV-2.","volume":"9","author":"Dhawan","year":"2023","journal-title":"Health Sci Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib227","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41587-024-02467-x","article-title":"Directed evolution of engineered virus-like particles with improved production and transduction efficiencies","volume":"43","author":"Raguram","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib228","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","article-title":"LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea","volume":"350","author":"Mirjalili Mohanna","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.02.014_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114861","article-title":"Lipid nanoparticle-mediated drug delivery to the brain","volume":"197","author":"Khare","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib230","doi-asserted-by":"crossref","DOI":"10.1038\/srep12497","article-title":"Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers","volume":"5","author":"Anand","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.02.014_bib231","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41565-023-01563-4","article-title":"Strategies for non-viral vectors targeting organs beyond the liver","volume":"19","author":"Kim","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.02.014_bib232","doi-asserted-by":"crossref","first-page":"20861","DOI":"10.1021\/acsnano.4c02380","article-title":"Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems","volume":"18","author":"Liu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.02.014_bib233","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib234","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib235","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.02.014_bib236","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1089\/scd.2010.0058","article-title":"Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double-strand DNA breaks","volume":"19","author":"Tichy","year":"2010","journal-title":"Stem Cell Dev"},{"key":"10.1016\/j.apsb.2026.02.014_bib237","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood-2015-05-646398","article-title":"MLL leukemia induction by genome editing of human CD34+ hematopoietic cells","volume":"126","author":"Buechele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.02.014_bib238","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature13902","article-title":"In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR\/Cas9 system","volume":"516","author":"Maddalo","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib239","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4005","article-title":"Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects","volume":"6","author":"Deng","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.02.014_bib240","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/life10120366","article-title":"Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome editing","volume":"10","author":"Lyu","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.apsb.2026.02.014_bib241","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ymthe.2020.11.009","article-title":"Single-base resolution: increasing the specificity of the CRISPR-Cas system in gene editing","volume":"29","author":"Rabinowitz","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib242","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib243","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-024-07552-4","article-title":"Bridge RNAs direct programmable recombination of target and donor DNA","volume":"630","author":"Durrant","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib244","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.02.014_bib245","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41392-022-01071-2","article-title":"A dual-specific CRISPR-Cas nanosystem for precision therapeutic editing of liver disorders","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib246","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1073\/pnas.1912220117","article-title":"Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing","volume":"117","author":"Chen","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.02.014_bib247","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41392-021-00645-w","article-title":"Spatiotemporal control of CRISPR\/Cas9 gene editing","volume":"6","author":"Zhuo","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.02.014_bib248","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1002\/anie.202005644","article-title":"Spatiotemporal delivery of CRISPR\/Cas9 genome editing machinery using stimuli-responsive vehicles","volume":"60","author":"Cai","year":"2021","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2026.02.014_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115346","article-title":"Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads","volume":"211","author":"Leandro","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.02.014_bib250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2023.05.005","article-title":"Bacterial molecular syringe for drug delivery","volume":"31","author":"Lu","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2026.02.014_bib251","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-023-05870-7","article-title":"Programmable protein delivery with a bacterial contractile injection system","volume":"616","author":"Kreitz","year":"2023","journal-title":"Nature"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352600119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352600119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:46:35Z","timestamp":1779414395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352600119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":251,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S221138352600119X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.02.014","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-viral delivery of genome-editing tools for treatment of genetic disorders","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}